Resolution Therapeutics announces upcoming presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025
– Dr Paul Brennan to present on the association of early biomarker modulation with long term clinical outcomes from the MATCH Ph II study of non-engineered macrophages in cirrhosis
– Dr Lara Campana to present on anti-inflammatory and anti-fibrotic effects of regenerative macrophage therapy in models of liver fibrosis
Edinburgh and London, UK, 9 October 2025 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy in inflammatory and fibrotic diseases, today announces two abstracts have been selected for presentation at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025. The conference will take place in Washington D.C., between 7-11 November 2025.
